Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
NCT05233397Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
A Phase 2 trial of tocilizumab in craniopharyngioma, sponsored by Nationwide Children's Hospital. Started Dec 2022; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
craniopharyngioma
Beyond the preview
Go deeper on NCT05233397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233397.